During the past decade, Metropolitan Eye Research and Surgery Institute conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 4 clinical trials were completed, i.e. on average, 44.4% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 4 clinical trials were completed. i.e. 133.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Metropolitan Eye Research and Surgery Institute" #1 sponsor was "Aldeyra Therapeutics, Inc." with 2 trials, followed by "Allakos Inc." with 1 trials sponsored, "Claris Biotherapeutics, Inc." with 1 trials sponsored, "Clearside Biomedical, Inc." with 1 trials sponsored and "Eyegate Pharmaceuticals, Inc." with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Metropolitan Eye Research and Surgery Institute" #1 collaborator was "Foresight Studies, LLC" with 1 trials as a collaborator, "Galapagos NV" with 1 trials as a collaborator, "Mallinckrodt" with 1 trials as a collaborator, "Ocular Imaging Research and Reading Center" with 1 trials as a collaborator and "Stanford University" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Metropolitan Eye Research and Surgery Institute" are "Non-infectious Anterior Uveitis" (2 trials), "Panuveitis" (2 trials), "Uveitis, Intermediate" (2 trials), "Uveitis, Posterior" (2 trials) and "Anterior Uveitis" (1 trials). Many other conditions were trialed in "Metropolitan Eye Research and Surgery Institute" in a lesser frequency.

Most popular intervention types in "Metropolitan Eye Research and Surgery Institute" are "Drug" (9 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "100 mM sodium citrate buffer solution" (1 trials), "40 mg/mL Dexamethasone phosphate ophthalmic solution" (1 trials), "4mg CLS-TA Suprachoriodal Injection" (1 trials), "ACTH (adrenocorticotropic hormone) gel" (1 trials) and "ADX-102 Ophthalmic Solution (0.5%)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Metropolitan Eye Research and Surgery Institute" are 10 trials for "All" genders.

Currently, there are NaN active trials in "Metropolitan Eye Research and Surgery Institute". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Metropolitan Eye Research and Surgery Institute, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Metropolitan Eye Research and Surgery Institute, 2 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".